Additionally, metformin inhibits mTORC1 via AMPK, which activates the potential insulin- and IGF-signaling pathways, consequently decreasing the harmful impacts of diabetes mellitus type 2 (including increased risk of cancer). This evidence concerns the gene IGF1 and cancer.